A5039735396- Mechanical Circulatory Support Devices
- Pulmonary Hypertension Research and Treatments
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Artificial Intelligence in Healthcare
- Family and Patient Care in Intensive Care Units
- Elevator Systems and Control
- Gastrointestinal Bleeding Diagnosis and Treatment
- Efficiency Analysis Using DEA
- Chronic Disease Management Strategies
- Occupational Health and Safety Research
- Health Policy Implementation Science
- Geriatric Care and Nursing Homes
- Congenital Heart Disease Studies
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Pancreatitis Pathology and Treatment
- Statistical Methods in Clinical Trials
- Pharmacy and Medical Practices
- Cardiac Valve Diseases and Treatments
- Digital Mental Health Interventions
- Advanced Statistical Process Monitoring
- Reliability and Maintenance Optimization
Carnegie Mellon University
2017-2020
University of Pittsburgh Medical Center
2019
University of Pittsburgh
2017-2018
Duke Medical Center
2016
Background Current risk stratification tools in pulmonary arterial hypertension (PAH) are limited their discriminatory abilities, partly due to the assumption that prognostic clinical variables have an independent and linear relationship outcomes. We sought demonstrate utility of Bayesian network-based machine learning enhancing predictive ability existing state-of-the-art tool, REVEAL 2.0. Methods derived a tree-augmented naïve Bayes model (titled PHORA) predict 1-year survival PAH patients...
Selection is a key determinant of clinical outcomes after left ventricular assist device (LVAD) placement in patients with end-stage heart failure. The HeartMate II risk score (HMRS) has been proposed to facilitate stratification and patient selection for continuous flow pumps. This study retrospectively assessed the performance HMRS predicting 90 day 1 year mortality within Interagency Registry Mechanically Assisted Circulatory Support (INTERMACS). A total 11,523 INTERMACS who received LVAD...
Left ventricular assist devices (LVADs) have consistently and successfully improved mortality associated with end-stage heart failure. However, the definition of an “optimal” outcome post LVAD as a benchmark remains debatable. We retrospectively examined patients in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) between 2012 2016 to assess 1 year post-LVAD “optimal outcome” defined patient who was alive on device or transplanted, New York Heart Association...
Pulmonary arterial hypertension (PAH) is a chronic and rapidly progressive disease that characterized by extensive narrowing of the pulmonary vasculature, leading to increases in vascular resistance, subsequent right ventricular dysfunction, eventual death. There are currently multiple approved drugs—developed as single or combination therapies last few years—that have improved outcome functionality PAH. However, despite improvement short-term survival with these new effective therapies, PAH...
Left ventricular assist devices (LVADs) are an increasingly common therapy for patients with advanced heart failure. However, implantation of the LVAD increases risk stroke, infection, bleeding, and other serious adverse events (AEs). Most post-LVAD AEs studies have focused on individual in isolation, neglecting possible interrelation, or causality between AEs. This study is first to conduct exploratory analysis discover sequential chains following that correlated important clinical...
Current risk stratification models to predict outcomes after a left ventricular assist device (LVAD) are limited in scope. We assessed the performance of Bayesian stratify post-LVAD mortality across various International Registry for Mechanically Assisted Circulatory Support (INTERMACS or IM) Profiles, types, and implant strategies. performed retrospective analysis 10,206 LVAD patients recorded IM registry from 2012 2016. Using derived algorithms 8,222 (derivation cohort), we applied...
Use of a left ventricular assist device (LVAD) can benefit patients with end stage heart failure, but only careful patient selection. In this study, Bayesian network models for predicting LVAD mortality at 1, 3, and 12 months post-implant were evaluated on retrospective data from single implant center. The performance these was better than the original model validation all three time points, receiver operating characteristic areas under curves (ROC AUCs) 78%, 76%, 75%, respectively....
Background. The decision to receive a permanent left ventricular assist device (LVAD) treat end-stage heart failure (HF) involves understanding and weighing the risks benefits of highly invasive treatment. goal this study was characterize HF patients across parameters that may affect their making inform development an LVAD support tool. Methods. A survey 35 at implant hospital performed information-seeking habits, interaction with physicians, technology use, numeracy, concerns about health....